Chronic Disease

The review, partly funded by Amgen, the maker of Riabni, makes the case for using the biosimilar to Rituxan for all indications of the originator.

Data gathered from electronic medical records found that the results in a real-world patient population with atopic dermatitis were consistent with those found in clinical trials.

New survey from American Medical Association identifies the continued burden of prior authorizations on physicians.

Rates dipped in the 1990s, but the opioid epidemic and the contaminated needles associated with it have caused an increase in new acute cases.

Safe and effective long-term treatment is important for stable disease control in atopic dermatitis.

Patients with eosinophilic esophagitis (EoE) are faced with delayed diagnosis, burdens related to symptoms, quality of life and cost, but lack targeted systemic therapies to improve long-term disease control.

Treating high levels of low-density lipoprotein cholesterol in young people may reduce lifetime exposure and lead to fewer cases of coronary heart disease.

States are putting caps on prices, and Semglee, the first interchangeable biosimilar in the United States, may exert some downward pressure.

Many people ignored heart disease signs and symptoms during the COVID-19 pandemic — sometimes with grave consequences.

After having thrived in a fee-for-service healthcare system, can chronic disease specialists be enticed to switch?

Research and investment are increasing into psilocybin and MDMA as treatments for several mental health disorders.

Multiple sclerosis is dependably among the most expensive chronic diseases to treat, but there are ways to reduce the size of the bill.

Paying attention to the social determinants of health may be a powerful way of improving cardiovascular outcomes.

Corticosteroids are a mainstay but the introduction of biologics has transformed the management of this severe form of asthma.

In this latest episode of MHE Talks: Improving Patient Access podcast, Dennis Bourdette, M.D., professor emeritus of neurology in the School of Medicine at the Oregon Health & Science University, spoke with Peter Wehrwein, senior editor of MHE. Bourdette, a nationally recognized expert on multiple sclerosis, discussed step therapy, tiers, insurance approvals and the need for greater communication between physicians and insurers.